title: [Cutaneous adverse drug reactions].
abstract: Cutaneous adverse drug reactions (CADR) represent a heterogeneous field including various clinical patterns without specific features suggesting drug causality. Exanthematous eruptions, urticaria and vasculitis are the most common forms of CADR. Fixed eruption is uncommon in western countries. Serious reactions (fatal outcome, sequelae) represent 2% of CADR: bullous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), DRESS (drug reaction with eosinophilia and systemic symptoms or drug-induced hypersensitivity syndrome) and acute generalized exanthematous pustulosis (AGEP). These forms must be quickly diagnosed to guide their management. The main risk factors are immunosuppression, autoimmunity and some HLA alleles in bullous reactions and DRESS. Most systemic drugs may induce cutaneous adverse reactions, especially antibiotics, anticonvulsivants, antineoplastic drugs, non-steroidal anti-inflammatory drugs, allopurinol and contrast media. Pathogenesis includes immediate or delayed immunologic mechanism, usually not related to dose, and pharmacologic/toxic mechanism, commonly dose-dependent or time-dependent. In case of immunologic mechanism, allergologic exploration is possible to clarify drug causality, with a variable sensitivity according to the drug and to the CADR type. It includes epicutaneous patch testing, prick test and intradermal test. However, no in vivo or in vitro test can confirm the drug causality. To determine the cause of the eruption, a logical approach based on clinical characteristics, chronologic factors and elimination of differential diagnosis is required, completed with a literature search. A reporting to pharmacovigilance network is essential in case of a serious CADR whatever the suspected drug and in any case if the involved drug is a newly marketed one or unusually related to cutaneous reactions.
authors.affiliation: Centre régional de pharmacovigilance du groupe hospitalier Pitié-Salpêtrière-Charles-Foix, AP-HP, coordination de pharmacovigilance d'Île-de-France, 47-83, boulevard de l'Hôpital, 75013 Paris, France. Electronic address: benedicte.lebrun-vignes@psl.aphp.fr.
authors.forename: B
authors.initials: B
authors.lastname: Lebrun-Vignes
authors.affiliation: Service de dermatologie, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France; Centre référence des maladies bulleuses immunologiques et toxiques, hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France.
authors.forename: L
authors.initials: L
authors.lastname: Valeyrie-Allanore
mesh_terms: D000970:Antineoplastic Agents; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology; D006801:Humans
chemical_list: D000970:Antineoplastic Agents
keywords: Cutaneous adverse drug reactions; Effets indésirables médicamenteux; Toxidermies